Develops non-invasive molecular tests for transplant patients.
Jun 2026Revenue $458M/yrExpenses $350M/yr
No trend
Figures by year
Is CareDx profitable?
Yes. In the 12 months to Jun 2026, revenue was $458M and expenses $350M.
| Fiscal year to | Revenue | Expenses | Operating profit |
|---|---|---|---|
| Dec 2025 | $380M | $411M | −$30.8M |
| Dec 2024 | $334M | $293M | $40.8M |
| Dec 2023 | $280M | $484M | −$203M |
| Dec 2022 | $322M | $399M | −$77.2M |
| Dec 2021 | $296M | $326M | −$29.7M |
| Dec 2020 | $192M | $215M | −$22.5M |
| Dec 2019 | $127M | $152M | −$24.5M |
| Dec 2018 | $76.6M | $92.1M | −$15.6M |
| Dec 2017 | $48.3M | $68.6M | −$20.3M |
| Dec 2016 | $40.6M | $78.0M | −$37.3M |
When the cash runs out, on the chart. A red line at the date the company’s cash would run out at its latest burn, so you can see whether it gets to break-even first. Part of a subscription.